Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-28
2010-10-05
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S370000, C548S184000, C548S190000
Reexamination Certificate
active
07807700
ABSTRACT:
The present invention relates to compounds with the formula (I), (II), (III) or (IV):wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.
REFERENCES:
patent: 4428948 (1984-01-01), Miller et al.
patent: 7253196 (2007-08-01), Henriksson et al.
patent: 2005/0009821 (2005-01-01), Pyring et al.
patent: 936 688 (1955-12-01), None
patent: 2164520 (1968-10-01), None
patent: WO 01-90091 (2001-11-01), None
patent: WO 01-90092 (2001-11-01), None
patent: WO 01-90093 (2001-11-01), None
patent: WO 01-90094 (2001-11-01), None
patent: WO 03-043999 (2003-05-01), None
patent: WO 03-044000 (2003-05-01), None
patent: WO 03-044009 (2003-05-01), None
patent: WO 2004-103980 (2004-12-01), None
patent: WO 2004-112779 (2004-12-01), None
patent: WO 2004-112781 (2004-12-01), None
patent: WO 2004-112782 (2004-12-01), None
patent: WO 2004-112783 (2004-12-01), None
patent: WO 2004-112784 (2004-12-01), None
patent: WO 2004-112785 (2004-12-01), None
patent: WO 2004-113310 (2004-12-01), None
patent: WO 2005-075471 (2005-08-01), None
patent: WO 2005/116002 (2005-12-01), None
Tilley et al., Journal of Medicinal Chemistry, 1979, 22(8), p. 1009-1010.
Wu and Farrelly, Toxicology 236:1-6, 2007.
Vippagunta et al., Advanced Drug Delivery Reviews, vol. 48, p. 3-26 (p. 3), 2001.
Okawara, et al.; “Preparations of Perhydroimidazo[1,5-a]pyridine-3-thiones and Thiazole-5-spirocyclopropan-4(5H)-ones from Thioureas and α,γ-Dibromobutyryl Chloride under Phase-transfer Conditions”;J. Chem. Soc.; Perkin Trans. I; 1986; pp. 1733-1735.
Doran et al.; “Dialkyl Thiazolidiones”,Journal of Organic Chemistry; vol. 3; 1938; pp. 193-197.
Kví{hacek over (c )}ala et al.; “Reactions of 3-chloropentafluoropropene-1,2-oxide with bifunctional nucleophiles: a new route to chlorodifluoromethyl-substituted heterocycles”;Journal of Fluorine Chemistry; vol. 108; 2001; pp. 1-5.
Hurst et al.; “The sysnthesis of some pyrimidinyl and thiazolyl ureas and thioureas and some related compounds”;Australian Journal of Chemistry; vol. 41; 1988; pp. 1221-1229.
King et al.; “The Reaction of Diazoketones with Thioamide Derivatives”;Journal of American Chemical Society, vol. 71; 1949; pp. 367-368.
Schreiner et al.; “A Convenient Protocol for Selective Cleavage of 2-Hydroxy Acid Amides. Application to Semisynthesis of the Cyclic Heptapeptide Aza HUN-7293”;Journal of Organic Chemistry; vol. 67; 2002; pp. 8299-8304.
Moore et al.; “sulfonamidothioazolones”Journal of American Chemical Society; vol. 63; 1941; pp. 2781-2784.
Dixon et al.; “Action between Thiourea and some Haloid Derivatives of Fatty Acids”;Journal of the Chemical Society; vol. 63; pp. 815-821.
Mittra et al.; “Reaction of Aromatic Aldehydes with 5-methyl-4-thiazolidones”;Journal of the Indian Chemical Society; vol. 36; No. 10; 1959; pp. 723-725.
Vasa et al.; “Thiazolidones Part I”;Journal of Indian Chemical Society; vol. 36; No. 9; 1959; pp. 648-650.
Andreasch, R.; “Zur Kenntniss der Thiohydantoïne”,Monatshefte Fur Chemie; vol. 8; 1887; pp. 407-424.
Heald et al.; “Syntheses of Certain Thiazolopyrimidines”;Journal of Chemical Society; 1950, pp. 1127-1129.
Aspelund, H., “Einwirkung von natriumhydroxyd auf einige 2-imino-4-oxazolidinone bzw. 2-amino-4-oxazolinone”,Acta Academiae Aboensis, ser. B, vol. 25, No. 5, 1965, pp. 1-21 (XP001246496).
Leistner, S., et al., “Darstellung von 3-oxo (bzw.imino)-5-(alpha-hydroxy-alkyl)-1,2,4-triaz olinderivaten aus 2-oxo(bzw.Imino)-4-oxo-5-alkyl-oxazolidine n und Hydazinhydrat”,Zeitschrift fuer Chemie, vol. 14, No. 7, 1974, pp. 267-268 (XP009062313).
Aspelund, H., “Einwirkung von natriumhydroxyd aud einige 2-imino-4-oxazolidinone bzw. 2-amino-4-oxazolinone”,Acta Academiae Aboensis, ser. B, vol. 26, No. 8, 1967, pp. 1-13 (XP001246495).
Rapi, G., et al., “Tautomerism of 2-amino-2-oxazolin-4-ones”,Journal of Heterocyclic Chemistry, vol. 9, No. 2; 1972; pp. 285-292 (XP002369328).
Erlenmeyer, H., et al, “Zer kenntnis der Eigenschaften isosterer und strukturahnlicher verbidungen VI. Uber einige derivate des thiazols und des oxazols”,Helvetica Chimica Acta, vol. 21, 1938, pp. 111-113 (XP009062356).
The Office Action received in the corresponding Canadian Patent Application No. 2,568,186, dated Feb. 18, 2009. (4 pgs.).
Mittra, et al., “Reaction of Aromatic Aldehydes with 5-Methyl-4Thiazolidones”,Jour. Indian Soc., vol. 36, 10, 1959, pp. 723-725.
The Office Action received in the corresponding Canadian Patent Application No. 2,568,186, dated Feb. 17, 2010.
Chizhevskaya, et al., Vesti Akademii Navuk BSSR, Serrya Khimichnykh Navuk, vol. 1, 1971, pp. 85-88.
Chizhevskaya, et al., Vesti Akamennii Navuk BSSR, Serrya Khimichnykh Navuk, vol. 6, 1970, pp. 78- 81.
Bartberger Michael D.
Bercot Eric
Cai Guolin
Fotsch Christopher H.
Frizzle Matthew J.
Amgen Inc.
Chu Yong
Foley & Lardner LLP
LandOfFree
Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157192